

Review of: "The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity"

Veronica Salau¹

¹ University of the Free State

Potential competing interests: No potential competing interests to declare.

Comments to Authors

Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a class of type 2 diabetes drugs that regulate blood glucose while reducing weight gain. Recent research have shown the potential of GLP-1-RAs to abet smoking abstinence. 'The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity' reported by Kok Kuan et al is a very interesting and well conceptualized review manuscript which creates a focal point for robust future studies on GLP-1R agonists. However, I have few suggestions for the authors which may improve this review manuscript.

The manuscript will be suitable for publication once the suggestions and comments are addressed.

-Considering that these risk factors (tobacco smoking, obesity and diabetes) of cardiovascular and other chronic diseases are globally prevalent, expanding the scope of the review (in terms of population) rather than limiting it to Singapore will add more value and greatly improve this manuscript. It is indeed a point of global interest.

-Authors should consider a graphical representation of the mechanisms of action of GLP-1 RA, highlighting its therapeutic application in diabetes and obesity.

-Lastly, I suggest articles (result section of the manuscript) discussed in the manuscript should also be summarized on a table. The table will give easy indication and representation of the explanations and comparisons, and make readers understand the authors points better.